ASML Q1 Beat Overshadowed by Q2 Sales Miss, Highlighting Execution Risks

What happened

ASML exceeded analyst expectations for Q1 earnings, demonstrating robust demand and operational strength in the first quarter. However, the company provided a Q2 sales outlook that missed estimates, leading to a stock decline as investors reacted to the near-term weakness. This disconnect underscores the persistent operational challenges in converting ASML's €38.8 billion backlog into accepted shipments, a core risk highlighted in the DeepValue report. While Q1 performance suggests underlying demand remains intact, the Q2 shortfall signals potential issues with supply chain bottlenecks or customer site acceptance delays that could impact revenue timing. The focus now shifts to whether ASML can uphold its full-year guidance of €34–39 billion in sales and 51–53% gross margins, which is critical for validating the current investment thesis.

Implication

The weaker Q2 outlook indicates ASML's operational throughput may be faltering, threatening its ability to efficiently convert backlog into revenue and potentially leading to a downward revision in full-year guidance, which would break the current investment thesis. This development aligns with the DeepValue report's bear-case scenario, where capacity constraints delay deliveries, posing a near-term headwind for the stock given its premium valuation multiples. However, if Q1 strength and the robust backlog persist, the issue might be temporary, but it necessitates close monitoring of upcoming quarterly updates for signs of shipment acceleration or margin pressure. Investors should prioritize management's commentary on supply chain dynamics and any narrowing of the FY2026 guidance range as key indicators of de-risking. Ultimately, with the stock priced at 45.1x P/E, even minor execution slippages could exacerbate downside risk, underscoring the importance of waiting for clearer evidence before considering an entry.

Thesis delta

The Q2 sales miss does not fundamentally shift the WAIT thesis but heightens the urgency around monitoring operational execution and guidance integrity. If this leads to a cut in full-year sales below €34 billion or gross margin below 51%, the thesis would break, necessitating a reassessment towards bear-case outcomes. Otherwise, the thesis remains dependent on ASML reiterating or tightening its FY2026 guidance in the next 3-6 months, as previously outlined.